Cytopathologic diagnosis was suspicious for papillary thyroid carcinoma and ThyroSeq molecular testing revealed an underlying CREB3L2::PPARγ fusion, implying a high risk for “malignancy or non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)”. The gene discussed is PPARG; the disease is differentiated thyroid carcinoma.